Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany-based Gene Bridges has given license to the Japanese pharmaceutical company Chugai Pharmaceutical, for the use of its Red/ET recombination technology. Patented in Japan, Red/ET is a method to generate targeting vectors or used in the modification of E. coli chromosomes.
Subscribe to our email newsletter
Recombineering with Red/ET will allow cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including large one such as BACs or the E.coli chromosome.
Red/ET Recombineering is one simple and powerful tool to modify plasmids, BACs, and even E.coli chromosomes.
Gary Stevens, CEO, Gene Bridges, said: “Red/ET is fast becoming the standard DNA engineering technology used in industry and academia worldwide.”
“Having recently also licensed Red/ET to Daiichi Sankyo and Takeda we are delighted to be signing this amendment to another leading Japanese Pharmaceutical company, which found the existing license agreement worthwhile expanding,” he added.